Related Experiment Videos
Prophylaxis against febrile convulsions with phenobarbital. A 3-year prospective investigation
Insights
This study evaluated phenobarbital for preventing recurrent febrile convulsions in children. While the treatment model helped identify high-risk patients, 12% experienced repeat convulsions despite therapeutic drug levels.
Area of Science:
- Pediatrics
- Neurology
- Clinical Pharmacology
Background:
- Febrile convulsions are common in children.
- Identifying children at high risk for recurrence is crucial for management.
- Long-term prophylactic treatment efficacy requires evaluation.
Purpose of the Study:
- To assess the effectiveness of continuous phenobarbital therapy in preventing recurrent febrile convulsions in children.
- To evaluate a risk-stratification model for managing children with febrile convulsions.
Main Methods:
- A cohort of 182 children with febrile convulsions was prospectively studied.
- Children were classified into five risk groups.
- High-risk children (Groups I-IV) received two years of phenobarbital therapy with regular serum concentration monitoring.
Main Results:
- Of 59 children completing therapy, 7 (12%) had recurrent febrile convulsions.
- Recurrences occurred despite therapeutic serum phenobarbital levels (70-120 mumol/l).
- No specific characteristics identified children with treatment failure.
Conclusions:
- The established therapeutic model effectively distinguished children with high risk for recurrent febrile convulsions.
- Continuous phenobarbital therapy showed limited efficacy in preventing recurrence in a subset of children, even with therapeutic serum levels.
Abstract:
An unselected patient material of 182 children admitted consecutively with febrile convulsions during a period of two years was classified into five risk-groups. Continuous phenobarbital therapy for two years was recommended for 113 children (Groups I--IV). These children were followed-up as out-patients for at least one year after admission. In children receiving phenobarbital therapy, serum concentrations were controlled every third month. A total of 59 children completed the treatment according to the directives given and seven of these (12%) developed renewed febrile convulsions despite serum phenobarbital concentrations within the therapeutic range (70--120 mumol/l). No particular characteristics for these children could be established on the basis of the parameters registered. The therapeutic model established was found to be suitable for distinguishing between children with massive risk for renewed convulsions (Group I--IV) compared with children for whom treatment was not recommended (Group V).